1stOncology™: Cancer Intelligence Service – Page 748 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

On November 27, 2024 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio (Press release, Revolution Medicines, NOV 27, 2024, View Source [SID1234648685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click here. An archived replay will be available on the "Events & Presentations" page of the Revolution Medicines website at View Source for at least 14 days following the live event.

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

On November 27, 2024 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, reported that members of the management team are scheduled to participate in a fireside chat at the 7 th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET (Press release, Geron, NOV 27, 2024, View Source [SID1234648684]).

A webcast of the fireside chat will be available through the Investors and Media section of Geron’s website under Events following the presentation. The webcast will be archived and available for replay for a period of 30 days.

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

On November 27, 2024 Exelixis, Inc. (Nasdaq: EXEL) reported that company management will participate in fireside chats at the following investor conferences in December (Press release, Exelixis, NOV 27, 2024, View Source [SID1234648683]):

Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City.
Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in Miami.
To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

On November 27, 2024 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET (Press release, CytomX Therapeutics, NOV 27, 2024, View Source [SID1234648682]).

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

On Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company’s potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer (Press release, Compugen, NOV 27, 2024, View Source [SID1234648681]).

U.S. Patent No. 12152084 titled "Triple combination antibody therapies" augments patents previously issued to Compugen by expanding and protecting the use of COM902 and backup antibodies for treating cancer patients, to include the triplet combination of COM902 with any anti-PD-1 antibody and any anti-PVRIG antibody.

"Protecting COM902 in combination with any anti-PVRIG antibody and any anti-PD-1 antibody is an important part of our strategy to bring innovative treatments to patients and value to our shareholders," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "Recent developments in the TIGIT landscape point to the potential advantage of anti-TIGITs without an active Fc binder such as COM902. Our data also suggest that blocking TIGIT may be insufficient to provide optimal anti-tumor activity in certain tumor types, including those non-responsive to PD-1 inhibition, and blocking PD-1 and PVRIG in parallel may be needed to provide optimal benefit. In our next study we plan to evaluate our potential first-in-class, anti-PVRIG antibody, COM701, in an adaptive platform trial designed to first establish its monotherapy benefit and as a potential backbone for future drug combinations, including with COM902, anti-PD-1 and others."

U.S. Patent No. 12152084 is expected to expire no earlier than August 2037 in the United States.November 27, 2024